石四药集团：盐酸屈他维林已获批登记成为在上市制剂使用的原料药

Group 1 - The core point of the article is that the company, Shijiazhuang Fourth Pharmaceutical Group, has received approval from the National Medical Products Administration of China for its raw material drug, Hydrochloride of Butylscopolamine, to be used in marketed formulations [1] Group 2 - Hydrochloride of Butylscopolamine is an antispasmodic drug primarily used for treating spasms in the biliary, urinary, and gastrointestinal tracts [1]